Cargando…

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports

Promising drug development efforts may frequently fail due to unintended adverse reactions. Several methods have been developed to analyze such data, aiming to improve pharmacovigilance and drug safety. In this work, we provide a brief review of key directions to quantitatively analyzing adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soldatos, Theodoros G., Kim, Sarah, Schmidt, Stephan, Lesko, Lawrence J., Jackson, David B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124355/ https://www.ncbi.nlm.nih.gov/pubmed/35143713 http://dx.doi.org/10.1002/psp4.12765

Ejemplares similares

Adverse Event Circumstances and the Case of Drug Interactions
por: Soldatos, Theodoros G., et al.
Publicado: (2019)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
por: Schotland, Peter, et al.
Publicado: (2020)

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development
por: Kim, Sarah, et al.
Publicado: (2022)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
por: Schaefer, Anne, et al.
Publicado: (2020)

In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis
por: Racz, Rebecca, et al.
Publicado: (2018)

Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
por: Kim, Sarah, et al.
Publicado: (2022)

2489. Adverse Events with Biktarvy: Post-Marketing Study
por: Hayes, Edwin, et al.
Publicado: (2019)

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2019)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

Reporting of adverse events for marketed drugs: Need for strengthening safety database
por: Apte, Aditi Anand
Publicado: (2016)

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

Predicting potential adverse events using safety data from marketed drugs
por: Daluwatte, Chathuri, et al.
Publicado: (2020)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
por: Pham, Phuong, et al.
Publicado: (2020)

Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports
por: Ekhart, Corine, et al.
Publicado: (2022)

Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system
por: Al-Ahmari, Abdullah K., et al.
Publicado: (2022)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Safety of Sublingual Immunotherapy: A Secondary Analysis of Post-marketing Adverse Events Reports Using a Japanese Public Database
por: Kaneda, Yudai, et al.
Publicado: (2023)

Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data
por: Algarni, Majed A.
Publicado: (2022)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
por: Alahmari, AK, et al.
Publicado: (2022)

Food Safety and Adverse Selection in Rural Maize Markets
por: Kadjo, Didier, et al.
Publicado: (2019)

Large-scale mining disease comorbidity relationships from post-market drug adverse events surveillance data
por: Zheng, Chunlei, et al.
Publicado: (2018)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy)
por: Stefanizzi, Pasquale, et al.
Publicado: (2023)

Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection
por: Xu, Rong, et al.
Publicado: (2014)

ADEpedia 2.0: Integration of Normalized Adverse Drug Events (ADEs) Knowledge from the UMLS
por: Jiang, Guoqian, et al.
Publicado: ( 201)

A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis
por: Fujiwara, Masakazu, et al.
Publicado: (2016)

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
por: Mina, Syeda A., et al.
Publicado: (2021)

Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China
por: Liu, Yu, et al.
Publicado: (2022)

Examining Socioeconomic and Computational Aspects of Vaccine Pharmacovigilance
por: Soldatou, Vasiliki, et al.
Publicado: (2019)

Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
por: Liu, Ruoqi, et al.
Publicado: (2019)

Adverse events and technical complaints related to central venous catheters marketed in Brazil
por: Morais, Luciene de Oliveira, et al.
Publicado: (2013)

Precision Oncology—The Quest for Evidence
por: Soldatos, Theodoros G., et al.
Publicado: (2019)

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
por: Lee, Chae Won, et al.
Publicado: (2022)

Post-marketing safety surveillance of the rotavirus vaccine in India
por: Kang, Gagandeep, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l2bleercekmlvkktksqe68vouf